Interventional × Head & Neck × Clear all
NCT02834013 2026-03-18

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
818 enrolled
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled